Immunotherapy of systemic sclerosis
dc.creator | Katsiari C.G., Simopoulou T., Alexiou I., Sakkas L.I. | en |
dc.date.accessioned | 2023-01-31T08:33:43Z | |
dc.date.available | 2023-01-31T08:33:43Z | |
dc.date.issued | 2018 | |
dc.identifier | 10.1080/21645515.2018.1491508 | |
dc.identifier.issn | 21645515 | |
dc.identifier.uri | http://hdl.handle.net/11615/74636 | |
dc.description.abstract | Systemic sclerosis (SSc) is a chronic systemic disease characterized by microvasculopathy, immune activation, and extensive collagen deposition. Microvasculopathy and immune activation occur very early in the disease process. Evidence from animal models and in vitro studies indicate that T-cells and B-cells activate fibroblasts to produce collagen. Traditional immunosuppressants, cyclophosphamide(CyP), methotrexate(MTX), and more recently mycophenolate mofetil(MMF), may prove more effective if used very early in the disease course. These drugs showed some benefit in skin (MTX, CyP, MMF) and lung function (CyP, MMF). Biologicals, such as intravenous immunoglobulin (IVIg), belimumab(Beli), tocilizumab(TCZ), abatacept(Aba), rituximab(RTX) and fresolimumab(Fresu) appear promising as they exhibited some benefit in skin (IVIg, Beli, TCZ, Aba, RTX, Fresu), hand function (IVIg), and joints (IVIg, TCZ, Aba). Autologous stem cell transplantation showed the best therapeutic efficacy on skin and internal organs, and looks very promising, as modification of transplantation immunosuppression is decreasing the early high mortality. © 2018, © 2018 Taylor & Francis. | en |
dc.language.iso | en | en |
dc.source | Human Vaccines and Immunotherapeutics | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85058674796&doi=10.1080%2f21645515.2018.1491508&partnerID=40&md5=2dacc6c555f9c29969750de0a2ffdb5b | |
dc.subject | abatacept | en |
dc.subject | azathioprine | en |
dc.subject | B cell activating factor | en |
dc.subject | belimumab | en |
dc.subject | cyclophosphamide | en |
dc.subject | dasatinib | en |
dc.subject | fresolimumab | en |
dc.subject | imatinib | en |
dc.subject | immunoglobulin | en |
dc.subject | methotrexate | en |
dc.subject | mycophenolate mofetil | en |
dc.subject | nilotinib | en |
dc.subject | placebo | en |
dc.subject | rapamycin | en |
dc.subject | rituximab | en |
dc.subject | tocilizumab | en |
dc.subject | anaphylaxis | en |
dc.subject | artery thrombosis | en |
dc.subject | aseptic meningitis | en |
dc.subject | asthma | en |
dc.subject | autologous stem cell transplantation | en |
dc.subject | bladder cancer | en |
dc.subject | bone marrow suppression | en |
dc.subject | chill | en |
dc.subject | cyclophosphamide-induced cystitis | en |
dc.subject | drug efficacy | en |
dc.subject | drug megadose | en |
dc.subject | fever | en |
dc.subject | gastrointestinal symptom | en |
dc.subject | gene expression | en |
dc.subject | hair loss | en |
dc.subject | human | en |
dc.subject | hypertriglyceridemia | en |
dc.subject | immunosuppressive treatment | en |
dc.subject | immunotherapy | en |
dc.subject | infection risk | en |
dc.subject | liver fibrosis | en |
dc.subject | liver toxicity | en |
dc.subject | low drug dose | en |
dc.subject | lung function | en |
dc.subject | migraine | en |
dc.subject | mortality | en |
dc.subject | myalgia | en |
dc.subject | nausea | en |
dc.subject | nausea and vomiting | en |
dc.subject | nonhuman | en |
dc.subject | overall survival | en |
dc.subject | phase 2 clinical trial (topic) | en |
dc.subject | randomized controlled trial (topic) | en |
dc.subject | Review | en |
dc.subject | rhinitis | en |
dc.subject | scoring system | en |
dc.subject | skin fibrosis | en |
dc.subject | systemic sclerosis | en |
dc.subject | treatment response | en |
dc.subject | Taylor and Francis Inc. | en |
dc.title | Immunotherapy of systemic sclerosis | en |
dc.type | other | en |
Dateien zu dieser Ressource
Dateien | Größe | Format | Anzeige |
---|---|---|---|
Zu diesem Dokument gibt es keine Dateien. |